NextWave Pharmaceuticals nextwavepharma.com


Public lists: Pharma Startups (4732)

NextWave Pharmaceuticals a specialty pharmaceutical company primarily focused on the development and commercialization of products for the treatment of ADHD and related CNS disorders. NextWave's flagship drug, Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, is used for the treatment of ADHD.

NextWave Pharmaceuticals a specialty pharmaceutical company primarily focused on the development and commercialization of products for the treatment of ADHD and related CNS disorders. NextWave's flagship drug, Quillivant XR (methylphenidate hydrochlo...Show all

Company (Acquired)

Phone: 408-342-1300

Fax:

20450 Stevens Creek Boulevard
Suite 150
Cupertino, 95014
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
NextWave Pharmaceuticals $95M Sep 25, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related NextWave Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Competitors

Company Status Description Investors

AkaRx

Paramus, New Jersey, United States
Alive / ActiveAkaRx develops therapeutic products including avatrombopag, which is an investigational oral thrombopoietin receptor agonist.Login to see details

Ikaria

Hampton, New Jersey, United States
AcquiredIkaria is a critical care company focused on developing and commercializing therapies designed to address the significant needs of critically ill patients. The company's product, INOMAX (Inhaled Nitric Oxide) is a vasodilator which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)